Astrazeneca Pharma India Ltd (ASTRAZEN) Stock Price & News

ASTRAZEN:NSE

Astrazeneca Pharma India Ltd

₹6,529.00

+0.76%

(+49.50) 1D

Nov 9, 3:30:00 PM GMT+5:30 · INR

All symbols

	Symbol	Price	Change	% Change

Last report

Nov 5, 2026

Fiscal period

Q2 2027

- / -

Revenue / Est. (INR)

7.29B / -

Fiscal Q2 2027 earnings call

Waiting for the earnings call

At a glance

Insights from the latest news and reports

Previous reportsAll values in INR

Loading Previous Earnings...

All values in INR	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Revenue	6.12B	5.79B	6.83B	7.29B
Cost of goods sold	3.66B	3.98B	4.47B	4.74B
Cost of revenue	3.66B	3.98B	4.47B	4.74B
Research and development expenses	-	-	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1.30B	-392.20M	1.10B	855.50M
Operating expense	2.04B	1.25B	1.92B	1.65B
Total operating expenses	5.71B	5.23B	6.39B	6.39B
Operating income	409.90M	556.00M	437.10M	902.20M
Other non operating income	51.30M	-175.20M	92.30M	151.20M
EBT including unusual items	465.40M	581.40M	507.50M	884.90M
EBT excluding unusual items	450.60M	593.50M	509.90M	1.03B
Income tax expense	139.50M	132.60M	128.20M	261.60M
Effective tax rate	29.97%	22.81%	25.26%	29.56%
Other operating expenses	694.70M	1.49B	741.30M	741.30M
Net income	325.90M	448.80M	379.30M	623.30M
Net profit margin	5.33%	7.76%	5.56%	8.55%
Earnings per share	-	-	-	-
Interest and investment income	-	232.00M	-	-
Interest expense	-10.60M	-20.40M	-19.50M	-18.90M
Net interest expenses	-10.60M	211.60M	-19.50M	-18.90M
Depreciation and amortization charges	38.40M	56.00M	52.30M	53.50M
EBITDA	493.98M	598.30M	479.40M	955.10M
Gain or loss from assets sale	-	-	-	-

Finance